ArticleCritical care (London, England)2020
Soluble urokinase plasminogen activator receptor (suPAR) as an early predictor of severe respiratory failure in patients with COVID-19 pneumonia.
2 registry-linked trialsOpen access · goldAbstract readLetter
In one paragraph
Article in Critical care (London, England), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 111 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
111citing papers in PubMed, 2 pooled it
3.7field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The International Study of Inflammation in COVID-19: A Prospective Multi-Center Observational Study Examining the Role of Biomarkers of Inflammation in Predicting Covid-19 Related Outcomes in Hospitalized Patients
The Role of Ischemia Modified Albumin in Patients With COVID-19
Who cites it
111 citing papers in PubMed, 2 syntheses or guidelines pooled it, 187 citations in OpenAlex.
- Endotheliopathy in Acute COVID-19 and Long COVID.International journal of molecular sciences · 2023Pooled it
- Novel inflammatory biomarkers in the prognosis of COVID-19.Therapeutic advances in respiratory diseasePooled it
- Safety of baricitinib in vaccinated patients with severe and critical COVID-19 sub study of the randomised Bari-SolidAct trial.EBioMedicine · 2025Trial
- qSOFA combined with suPAR for early risk detection and guidance of antibiotic treatment in the emergency department: a randomized controlled trial.Critical care (London, England) · 2024Trial
- Facilitating Safe Discharge Through Predicting Disease Progression in Moderate Coronavirus Disease 2019 (COVID-19): A Prospective Cohort Study to Develop and Validate a Clinical Prediction Model in Resource-Limited Settings.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022Trial
- Soluble urokinase plasminogen activator receptor levels are predictive of COVID-19 severity in Afro-Caribbean patients.Biomarkers in medicine · 2022Trial
- Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial.Nature medicine · 2021Trial
- Trial
- Evaluating plasma ferritin and suPAR as treatable traits for critically ill patients with COVID-19 treated with anakinra: an exploratory analysis of the immune modulation domain of the REMAP-CAP randomised clinical trial.Critical care (London, England) · 2026Observational
- Sepsis associated with Clostridioides difficile infection carries similar mortality to sepsis of other origin: a propensity score-matched analysis.Scientific reports · 2026Observational
- Insight to Neglected Biomarkers in COVID-19: A Comprehensive Narrative Review".Biomarker insights · 2026Review
- Biomarkers and early-onset acute kidney injury in critically ill COVID-19 patients, a prospective monocentric observational study.BMC nephrology · 2025Observational
- 29-mRNA host response signatures for classification of bacterial infection, viral infection and disease progression in COVID-19 pneumonia: a post hoc analysis of the SAVE-MORE randomized clinical trial.Intensive care medicine experimental · 2025Article
- Advances in Understanding Inflammation and Tissue Damage: Markers of Persistent Sequelae in COVID-19 Patients.Journal of clinical medicine · 2025Review
- Soluble Urokinase Plasminogen Activator Receptor: A Promising Biomarker for Mortality Prediction Among Critical ED Patients.International journal of molecular sciences · 2025Article
- The dynamic role of soluble urokinase plasminogen activator receptor (suPAR) in monitoring coagulation dysfunction during COVID-19 progression: a review.Annals of medicine and surgery (2012) · 2025Review
- Soluble Urokinase Plasminogen Activator Receptor: A Useful Marker for Predicting Mortality in COVID-19 Patients.Cureus · 2024Article
- Evaluation of Soluble Urokinase Plasminogen Activator Receptor in COVID-19 Patients.Journal of clinical medicine · 2024Article
- Observational
- Potential Nephroprotective Effect of uPA against Ischemia/Reperfusion-Induced Acute Kidney Injury in αMUPA Mice and HEK-293 Cells.Biomedicines · 2024Article
51 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
6 authors at 5 institutions in 3 countries.
Nikoletta Rovina1st Department of Pulmonary Medicine and Intensive Care Unit, National and Kapodistrian University of Athens, Medical School, 115 27, Athens, Greece.
Karolina AkinosoglouDepartment of Internal Medicine, University of Patras, Medical School, 265 04, Rio, Greece.
Jesper Eugen-OlsenClinical Research Centre, Copenhagen University Hospital, Hvidovre, Denmark.
Salim HayekDepartment of Medicine, University of Michigan, Ann Arbor, MI, 48103, USA.
Jochen ReiserDepartment of Medicine, Rush University Medical Center, 1717 West Congress Parkway, Chicago, IL, 60612, USA. jochen_reiser@rush.edu.
Evangelos J Giamarellos-Bourboulis4th Department of Internal Medicine, National and Kapodistrian University of Athens, Medical School, 124 62, Athens, Greece. egiamarel@med.uoa.gr.
National and Kapodistrian University of Athens · GRCopenhagen University Hospital · DKRush University Medical Center · USUniversity of Michigan–Ann Arbor · USUniversity of Patras · GR
Funding
Extracorporeal SuPAR Extraction to Prevent COVID-19-associated Acute Kidney InjuryR01DK128012 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI HAYEK, SALIM · 2021 to 2021
$327kNIDDK NIH HHS R01 DK128012
Abstract
PubMed holds no abstract for this paper.
Indexed as
AgedBetacoronavirusBiomarkersClinical Laboratory TechniquesCoronavirus InfectionsCOVID-19COVID-19 TestingFemaleHumansImmunoenzyme TechniquesMaleMiddle AgedPandemicsPneumonia, ViralReceptors, Urokinase Plasminogen ActivatorRespiratory InsufficiencyBiomarkersPLAUR protein, humanReceptors, Urokinase Plasminogen ActivatorCOVID-19PrognosisRespiratory failuresuPAR
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
NCT04818866ClinicalTrials.gov
NCT05286268ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.